港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

579.360

+1.4270.25%

漲家數：14

跌家數：17

平家數：3

市盈率：- -

高：598.497

開：578.227

低：573.488

收：577.933

成交量：1.15億

成交額：33.86億

市值：3,682.12億

流通市值：3,290.33億

資料載入中...

總覽新聞資訊

先瑞達醫療-B(06669)公布2025年業績淨利約1.19億元按年增長128%

基石藥業-B(02616)公布PD-1/VEGF/CTLA-4三特異性抗體CS2009的最新臨床進展及I/II期關鍵臨床數據

《藍籌》中生製藥(01177.HK)全年純利跌33% 基本溢利增31.4% 末期息5港仙

阿斯达克财经

華領醫藥-B(02552)委任歐陽麗妮為公司秘書

一品紅(300723.SZ)子公司創新藥APH03571片獲得臨床試驗註冊申請受理

榮昌生物(09995)出現大手賣出12.5萬股，成交價$88.6，涉資1.108千萬

阿斯达克财经

天聖製藥曾因年報虛假引發索賠，部分案件已遞交立案

「AI製藥」的晶泰控股扭虧虛與實

华尔街见闻

老百姓大藥房與信達生物深化戰略合作攜手共拓創新藥市場

新股消息 | 據報聞泰醫藥擬赴港上市募資規模約為1億至2億美元

沛嘉醫療(09996)發布2025年度業績：穩中求進、提質增效核心業務穩健增長

智通财经网

河北省定州市市場監管局開展醫療器械經營環節法規宣貫培訓

中国质量新闻网

康寧傑瑞公布2025年度業績及近期業務進展

漢方製藥獨家產品捲入行賄案上個月剛披露H股招股書

康方生物(09926)出現大手買入8.1萬股，成交價$124.3，涉資1.007千萬

阿斯达克财经

《大行》華泰證券：吉利德收購Ouro反映康諾亞(02162.HK)平台價值

阿斯达克财经

強業績提振，港股通創新藥逆市續漲，520880收復20日線！樂普生物-B績後狂飆14%

港股異動 | 基石藥業-B(02616)再升逾4% 核心商業化產品舒格利單抗獲ESMO指南【I, A】級推薦

港股沛嘉醫療-B早盤升逾6%

每日经济新闻

國家醫保局醫藥服務管理司司長黃心宇：長護險制度建設可以從市地級統籌先起步不搞「齊步走」、「一刀切」

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":579.3598,"timestamp":1774512495612,"preClose":577.93304,"halted":0,"volume":115336870,"delay":0,"changeRate":0.002469,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":1.426758,"latestTime":"03-26 16:00:00","open":578.2267,"high":598.49725,"low":573.4878,"amount":3386124743,"amplitude":0.043274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.004143,"increases":13,"decrements":20,"flats":0,"marketCap":368211528480,"floatMarketCap":329033220336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.043274,"preClose":577.93304,"low":573.4878,"pbRate":"5.179109","latestPrice":579.3598,"volume":115336870,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.004143,"peRate":-60.041027,"marketCap":368211528480,"floatMarketCap":329033220336,"timestamp":1774512495612,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":17,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622285850","title":"先瑞達醫療-B(06669)公布2025年業績 淨利約1.19億元 按年增長128%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285850","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622285850?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 17:09","pubTimestamp":1774516180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先瑞达医疗-B 公布2025年业绩，收益约6.45亿元，同比增长20.7%;毛利约4.76亿元，同比增长18.3%;年内溢利约1.19亿元，同比增长128%;每股基本盈利0.4元。2025年是产品获批的收获期，公司成熟的多元化研发技术组合的协同效应取得成果。于报告期间，公司共获得国家药监局及北京药监局对11款产品的注册批准，其中多项产品代表了公司的里程碑式发布。同时，公司继续扩大全球布局。公司的外周射频消融系统于2025年10月获得美国FDA的510认证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06669","BK1100","BK1574"],"gpt_icon":0},{"id":"2622858900","title":"基石藥業-B(02616)公布PD-1/VEGF/CTLA-4三特異性抗體CS2009的最新臨床進展及I/II期關鍵臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2622858900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622858900?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 17:09","pubTimestamp":1774516159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新临床进展。在肺癌中展现强劲疗效：CS2009单药针对肺癌的I/II期初步疗效资料积极。截至2026年3月中旬，I期研究已共入组113例晚期实体瘤患者，中位元随访期约为6个月;II期研究已共入组85例患者。在TME中，PD-1和 CTLA-4的双重阻断作用通过与VEGFA的交联显著增强。同时，CS2009可优先结合PD-1和CTLA-4双阳性的肿瘤浸润T细胞，并最大程度上弱化对外周T细胞中CTLA-4调节通路的干扰。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK4023","LU1169589451.USD","BK1574","BK1161","PD","02616"],"gpt_icon":0},{"id":"2622483063","title":"《藍籌》中生製藥(01177.HK)全年純利跌33% 基本溢利增31.4% 末期息5港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2622483063","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622483063?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:37","pubTimestamp":1774514220,"startTime":"0","endTime":"0","summary":"中国生物制药公布2025年度业绩，收入318.34亿人民币(下同)，按年升10.3%。股东应占溢利23.43亿元，按年跌33%；每股盈利13.02分。连同已派发中期股息每股5港仙，全年合共派发股息每股10港仙。过往派息公布日期派息事项派息内容2025/08/18中期业绩股息：港元 0.05002025/03/20末期业绩股息：港元 0.0400 2024/08/13中期业绩股息：港元 0.03002024/03/28末期业绩股息：港元 0.0300若撇除已终止经营业务、若干非现金项目及联营公司影响，基本溢利45.41亿元，按年升31.4%。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512865/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512865/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","HK0000165453.HKD","01477","BK1574","BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","BK1191","IE00BZ08YT58.USD","BK1521"],"gpt_icon":0},{"id":"2622583727","title":"華領醫藥-B(02552)委任歐陽麗妮為公司秘書","url":"https://stock-news.laohu8.com/highlight/detail?id=2622583727","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622583727?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:34","pubTimestamp":1774514093,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华领医药-B(02552)发布公告，袁颕欣女士(袁女士)已辞任本公司公司秘书及不再担任根据香港联合交易所有限公司证券上市规则第 3.05条所规定的本公司授权代表，均自2026年3月26日起生效。在袁女士辞任后，董事会欣然宣布委任欧阳丽妮女士(欧阳女士)为本公司公司秘书及上市规则规定的第3.05条所规定授权代表，均自2026年3月26日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02552","BK1191"],"gpt_icon":0},{"id":"2622547837","title":"一品紅(300723.SZ)子公司創新藥APH03571片獲得臨床試驗註冊申請受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2622547837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622547837?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:20","pubTimestamp":1774513225,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03571片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH03571是公司研制的拟用于携带 FLT3(全称：FMS-like tyrosine kinase3，译为 FMS 样酪氨酸激酶 3)突变的复发性或难治性急性髓系白血病(acutemyelogenous leukemia，简称：AML)成人患者的治疗药品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","159992","BK0239","BK1574","300723"],"gpt_icon":0},{"id":"2622837509","title":"榮昌生物(09995)出現大手賣出12.5萬股，成交價$88.6，涉資1.108千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837509","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 16:08","pubTimestamp":1774512480,"startTime":"0","endTime":"0","summary":"[大手成交]荣昌生物(09995)在下午04:08出现大手卖出，成交量为12.5万，成交价为港币$88.6，涉资1.108千万。至目前为止，股价跌3.328%，今日最高价为$96.65，而最低价为$86.8，总成交量为633.599万股，总成交金额港币$5.81亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603267149/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603267149/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09995","BK0239","LU2488822045.USD","688331","LU1064130708.USD","LU1969619763.USD","BK1574","BK1583","LU2148510915.USD","LU2328871848.SGD","LU1064131003.USD"],"gpt_icon":0},{"id":"2622250834","title":"天聖製藥曾因年報虛假引發索賠，部分案件已遞交立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2622250834","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622250834?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 15:33","pubTimestamp":1774510380,"startTime":"0","endTime":"0","summary":"　　上海沪紫律师事务所刘鹏律师团队近日递交了一批次案件至法院立案，目前还在征集受损股民中。2025年11月8日，天圣制药公告收到中国证监会重庆证监局出具的《行政处罚决定书》。作为业内资深证券维权律师，刘鹏律师精准把握案件核心，诉讼经验丰富，索赔策略高效，为投资者争取最大权益，维权实力行业领先。专业决定胜算，经验确保结果，首选刘鹏律师，让您的索赔更稳妥、更高效！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-03-26/doc-inhsicuw2818235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2622783996","title":"「AI製藥」的晶泰控股扭虧虛與實","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783996","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783996?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:52","pubTimestamp":1774507932,"startTime":"0","endTime":"0","summary":"港股“AI制药明星企业”晶泰控股交出了上市以来的首份扭亏答卷。\n2025年，晶泰控股实现营业收入8....","market":"sg","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3768447","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3768447","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“AI制药”的晶泰控股扭亏虚与实","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","AIPO","AGIX","02228","BK1574","BK1141","BK1617","CHAT","BK1191"],"gpt_icon":0},{"id":"2622783622","title":"老百姓大藥房與信達生物深化戰略合作 攜手共拓創新藥市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783622","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783622?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:24","pubTimestamp":1774506240,"startTime":"0","endTime":"0","summary":"本报讯受处方外流持续推进影响，对于部分进院难度较大的创新药，零售药房已成为实现商业化落地、提升患者可及性的重要渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685418646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0502904849.HKD","BK1161","BK1589","603883","LU2097828474.EUR","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828557.USD","BK1583","HK0000165453.HKD","BK0209","159992","LU2242644610.SGD","01801","06978","BK1574","LU2097828714.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2622836858","title":"新股消息 | 據報聞泰醫藥擬赴港上市 募資規模約為1億至2億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622836858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622836858?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 14:23","pubTimestamp":1774506210,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体消息，成都闻泰医药科技股份有限公司Vincentage Pharma正考虑赴港上市，拟募资规模约为1亿至2亿美元。公司最受关注的管线是口服小分子GLP-1受体激动剂VCT220，也被称为CX11。公开信息显示，CX11已在中国进行II期临床试验，并显示出“有竞争力的减重效果”，其III期临床已于2024年底启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","09939","BK1574","159938"],"gpt_icon":0},{"id":"2622833544","title":"沛嘉醫療(09996)發布2025年度業績：穩中求進、提質增效 核心業務穩健增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833544","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833544?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 13:16","pubTimestamp":1774502207,"startTime":"0","endTime":"0","summary":"3月25日，沛嘉医疗(09996)发布了截至2025年12月31日止十二个月(“报告期”)的年度业绩。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260326/20260326131606_90636.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260326/20260326131606_90636.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09996","159891","BK1100","BK1574","BK1583"],"gpt_icon":0},{"id":"2622833510","title":"河北省定州市市場監管局開展醫療器械經營環節法規宣貫培訓","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833510","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622833510?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 13:15","pubTimestamp":1774502100,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 为进一步规范医疗器械经营秩序，压实企业主体责任，保障公众用械安全，近期，河北省定州市市场监督管理局对全市156家医疗器械经营企业开展了三期医疗器械经营环节法规宣贯培训。下一步，该局将以此次培训宣贯为契机，压紧压实企业质量安全主体责任，不断强化医疗器械质量监管，依法严厉打击违法违规行为，切实保障公众用械安全。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-26/doc-inhshxny2864385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","159883","09996","BK1574","BK1222","BK1583","09997"],"gpt_icon":0},{"id":"2622835709","title":"康寧傑瑞公布2025年度業績及近期業務進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2622835709","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622835709?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 13:14","pubTimestamp":1774502040,"startTime":"0","endTime":"0","summary":"苏州2026年3月26日 /美通社/ -- 康宁杰瑞生物制药公布了截至2025年12月31日的2025年度业绩和近期业务进展。财务概览  2025年度实现营业收入566.24百万元人民币，其中归属于本公司的产品收入130.13百万元人民币。2025年度年内亏损113.95百万元人民币。财务状况安全稳健，截至2025年12月31日现金储备为1350.32百万元人民币。2025年4月，KN026联合白蛋白结合型多西他赛HB1801一线治疗HER2阳性复发转移性乳腺癌的Ⅲ期临床研究完成全部患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4919913_ZH19913_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","LU0348723411.USD","LU1992135399.USD","BK4148","BK1574","LU2322448957.HKD","LU1720051108.HKD","LU1992135472.HKD","LU1720051017.SGD","BK1161","09966","LU2272731600.USD","LU2473716301.USD","LU2357305700.SGD","BK4588","LU2272731782.SGD","LU2272731865.HKD","LU1548497426.USD","BK4512","LU2322448791.USD","IE00BFMHRM44.USD"],"gpt_icon":1},{"id":"2622887076","title":"漢方製藥獨家產品捲入行賄案 上個月剛披露H股招股書","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887076","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887076?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:37","pubTimestamp":1774496231,"startTime":"0","endTime":"0","summary":"中国经济网北京3月26日讯 国家医保局网站3月24日通报了“张某猛药品销售行贿案”。2024年10月，河北省秦皇岛市山海关区人民法院依法组成合议庭，适用普通程序公开开庭审理了张某猛行贿、对非国家工作人员行贿案。　　汉方制药于2月25日向港交所递交了招股书，拟于主板上市。据招股书显示，汉方制药成立于2004年，从事中医药产品研发、生产及销售业务。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/26/20260326934314.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260326/32100470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2622880365","title":"康方生物(09926)出現大手買入8.1萬股，成交價$124.3，涉資1.007千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2622880365","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622880365?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:34","pubTimestamp":1774496040,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午11:34出现大手买入，成交量为8.1万，成交价为港币$124.3，涉资1.007千万。至目前为止，股价升2.053%，今日最高价为$129.7，而最低价为$124.1，总成交量为880.26万股，总成交金额港币$11.197亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603265100/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B5MMRT66.SGD","09926","LU0634319403.HKD","LU2476274720.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","BK1161","LU0348825331.USD","LU0348783233.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348735423.USD","LU1961090484.USD","LU0417516738.SGD","BK1574","LU0348766576.USD","LU0348784397.USD","LU0417516571.SGD","LU2476274308.USD","LU0348767384.USD","LU1720050803.USD","LU2778985437.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2622887191","title":"《大行》華泰證券：吉利德收購Ouro反映康諾亞(02162.HK)平台價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887191","media":"阿斯达克财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887191?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:21","pubTimestamp":1774495260,"startTime":"0","endTime":"0","summary":"华泰证券发表报告指，康诺亚-B公告吉利德将以16.75亿美元首付款、5亿美元里程碑并购Ouro，后者为承载CM336海外权益的NewCo。交易完成后，康诺亚依据Ouro股权将取得2.5亿元首付款及7,000万美元里程碑，同时继续享有CM336的销售分成权利。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419164250683_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512718/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0276","LU0531971595.HKD","BK1583","LU1934453819.USD","LU0164865239.USD","LU2148510915.USD","LU1064131003.USD","BK1574","BK1161","LU1328615791.USD","LU0871576103.HKD","LU1580142542.USD","BK0028","BK1587","LU1781817850.SGD","02162","601688","BK0188","LU1808992512.USD","BK0183","LU1979443071.USD","LU0039217434.USD","BK0012","LU1064130708.USD"],"gpt_icon":0},{"id":"2622882066","title":"強業績提振，港股通創新藥逆市續漲，520880收復20日線！樂普生物-B績後狂飆14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882066","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882066?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 11:03","pubTimestamp":1774494180,"startTime":"0","endTime":"0","summary":"3月26日，港股通医药再度逆市表现，100%创新药研发标的——港股通创新药ETF华宝、港股医疗核心资产——港股通医疗ETF华宝双双高开，一度携手涨超1%！520880量价齐升，盘中收复20日线，实时成交超2亿元。　　创新药多股领跑，乐普生物-B盘中飙升逾14%站上半年线，领涨所有港股通标的。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-26/doc-inhshtfa2929921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","VXUS","520880","06978","BK1574","02157","BK4585","BK4588","159992"],"gpt_icon":0},{"id":"2622821058","title":"港股異動 | 基石藥業-B(02616)再升逾4% 核心商業化產品舒格利單抗獲ESMO指南【I, A】級推薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821058","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821058?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:53","pubTimestamp":1774493593,"startTime":"0","endTime":"0","summary":"消息面上，3月25日，基石药业-B发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","BK1574","BK4585","02616","VXUS"],"gpt_icon":0},{"id":"2622444882","title":"港股沛嘉醫療-B早盤升逾6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622444882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622444882?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:47","pubTimestamp":1774493260,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月26日，沛嘉医疗-B(09996.HK)早盘涨超6%，截至发稿涨6.69%，报6.06港元，成交额1185.39万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685222031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685222031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159891","09996","BK4585","BK1100","BK4588","BK1583","VXUS","BK1574"],"gpt_icon":0},{"id":"2622882934","title":"國家醫保局醫藥服務管理司司長黃心宇：長護險制度建設可以從市地級統籌先起步 不搞「齊步走」、「一刀切」","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882934","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622882934?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:46","pubTimestamp":1774493160,"startTime":"0","endTime":"0","summary":"3月26日金融一线消息，国务院新闻办公室举行新闻发布会，介绍加快建立长期护理保险制度有关情况。国家医保局医药服务管理司司长黄心宇在国新办新闻发布会上表示，《关于加快建立长期护理保险制度的意见》规定用三年左右的时间，基本建立适应我国基本国情的长期护理保险制度。到2028年底，这项制度要在全国基本上全面覆盖。\n　　黄心宇指出，从统筹层次上，可以从市地级统筹先起步，也可以根据当地实际情况探索省级统筹。有条件的市地可以先行，不具备条件的市地可以先夯实条件之后再实施，总的来说是不搞“齐步走”、不搞“一刀切”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：秦艺","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/insurance/2026-03-26/doc-inhshnwy0399508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","09939","159938","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":295,"code":"91000000","status":"200"}]}}